EV71 VP0 Specific Neutra™ Antibody Products

Are you struggling with the challenges of developing effective interventions against severe hand, foot, and mouth disease (HFMD) and associated neurological complications? Our EV71 VP0 Specific Neutra™ Antibody Products leverage advanced structural virology and high-throughput hybridoma screening to deliver highly specific neutralizing antibodies, accelerating your antiviral therapeutic and vaccine development pipelines.

Introduction to Enterovirus 71 Capsid Protein VP0

Enterovirus 71 (EV71) Capsid protein VP0 is a critical precursor and structural component essential for viral infectivity. As a key part of the protomeric unit, VP0 is cleaved into VP2 and VP4 during final virion maturation, a step crucial for the stability and infectivity of the mature virus particle. EV71 VP0 is a highly conserved structural protein among Enterovirus A species. It is expressed as part of the polyprotein and is integral to the assembly of the viral capsid.

• Structural Insights

The EV71 capsid is an icosahedral assembly of 60 protomers, each containing one copy of VP0, VP1, and VP3. High-resolution cryo-EM structures reveal that VP0 contributes significantly to the stability of the protomer interface and the integrity of the canyon region, which is involved in receptor binding. Conformational changes during VP0 cleavage are pivotal for creating a stable, mature virion.

Fig.1 The EV71 A-particle serves as a gateway facilitating genome release: A CryoEM investigation of picornavirus uncoating.¹

• Resistance and Signaling Pathways

EV71 infection, facilitated by successful capsid assembly, triggers intense host immune and inflammatory responses. It can activate pathways such as the RIG-I-like receptor pathway for antiviral interferon response and the NLRP3 inflammasome pathway, leading to cytokine storm, which is particularly associated with severe neurological pathogenesis.

• Clinical Impact

EV71 is a primary etiological agent of HFMD and is notorious for causing severe neurological complications, including aseptic meningitis, brainstem encephalitis, and acute flaccid paralysis, especially in young children.

• Antibodies Against EV71 VP0
  Neutralizing antibodies targeting conformational epitopes on VP0 offer a potent strategy to combat EV71 infection.
  • Block viral uncoating or destabilize the capsid prior to mature cleavage.
  • Prevent receptor attachment by inducing conformational changes in the capsid.
  • Provide critical tools for vaccine immunogenicity assessment and therapeutic development.

Applications of Anti-EV71 VP0 Neutralizing Antibodies

Fig.2 Characterization of anti-EV71 VP0 mAbs that neutralize EV71.²

• Therapeutic Intervention for Severe HFMD

Anti-EV71 VP0 neutralizing antibodies present a direct therapeutic avenue for treating severe infections. By binding to conformational epitopes, these antibodies can neutralize circulating virions, reduce viral load, and mitigate neuroinflammation. In preclinical models, passive immunization with VP0-targeting antibodies has demonstrated efficacy in decreasing mortality and neurological sequelae, highlighting their potential for clinical translation in managing life-threatening EV71 encephalitis.

• Vaccine Efficacy and Immunogenicity Assessment

Our high-specificity anti-VP0 antibodies are indispensable reagents for evaluating vaccine candidates. They enable precise quantification of VP0-specific neutralizing antibody titers in serum from vaccinated individuals or animal models. This application is critical for determining correlates of protection, benchmarking vaccine potency, and ensuring batch-to-batch consistency during vaccine development and production.

Our Anti-EV71 VP0 Neutralizing Antibodies

Creative Biolabs delivers premium antibody solutions engineered for excellence in EV71 research and development:

• High Neutralizing Potency: Antibodies are rigorously validated for neutralizing activity against multiple EV71 genotypes using standardized plaque reduction neutralization tests.
• Superior Specificity: Produced using full-length, properly folded recombinant VP0 antigen, ensuring recognition of native conformational epitopes without cross-reactivity to related enteroviruses.
• Robust Validation: Each batch is comprehensively validated in key applications, including ELISA, Western Blot, Immunofluorescence, and Neutralization Assays, guaranteeing reproducible results.
• Tailored Formats: Available in various formats to suit diverse experimental needs, from structural studies to in vivo efficacy testing.

With more than twenty years of specialized experience in virology and antibody development, Creative Biolabs serves as your dependable collaborator in infectious disease research. We integrate extensive scientific expertise with advanced technology to deliver researchers reliable, high-performance antibody tools that expedite discovery processes. Our EV71 VP Specific Neutra™ Antibody Products exemplify our dedication to quality, innovation, and facilitating your progression from fundamental research to therapeutic advancements. Reach out to our scientific team today to discuss your project and request comprehensive product specifications.

References

1. Shingler, Kristin L., et al. "The enterovirus 71 A-particle forms a gateway to allow genome release: a cryoEM study of picornavirus uncoating." PLoS pathogens 9.3 (2013): e1003240. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1371/journal.ppat.1003240
2. Arthur Huang, Kuan-Ying, et al. "Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children." Nature Communications 8.1 (2017): 762. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s41467-017-00736-9